Change over period: —
NSE · BIOCON
BIOCON LTD.
-17.9% from the 52-week high · +11.9% above the low
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,408 full-time employees. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
The short version. BIOCON LTD. reported revenue of ₹4,389 crore for Sep 2026, up 2.2% from a year earlier. Net profit was ₹41 crore (down 51.2% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 44.67% in Sep 2026, down 15.97 points over 8 quarters.
1 · The price
How has the stock traded?
BIOCON LTD. trades 17.9% below its 52-week high and 11.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹4,389 cr.
Sep 2026 net profit of ₹41 cr.
1.1 pts lower than a year earlier.
Revenue compounded at 14.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4389 | 4336 | 4517 | 4173 | 4296 | 3942 | 4417 | 3821 |
| Net profit | 41 | 141 | 126 | 144 | 84 | 31 | 344 | 25 |
| Net margin % | 0.9 | 3.3 | 2.8 | 3.4 | 2.0 | 0.8 | 7.8 | 0.7 |
| EPS (₹) | 0.25 | 0.87 | 0.78 | 1.08 | 0.63 | 0.23 | 2.87 | 0.21 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16927 | 15262 | 14756 | 11174 | 8184 | 7106 | 6367 | 5514 |
| Net profit | 386 | 1013 | 1022 | 463 | 648 | 740 | 748 | 905 |
| Net margin % | 2.3 | 6.6 | 6.9 | 4.1 | 7.9 | 10.4 | 11.8 | 16.4 |
| EPS (₹) | 2.38 | 8.44 | 8.52 | 3.85 | 5.4 | 6.17 | 6.24 | 7.54 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 1.1% in Mar 2026; debt to equity is 0.44.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 1.1 | 4.7 | 5.2 | 2.6 |
| Return on capital % | 2.9 | 6.3 | 6.3 | 3.4 |
| EBITDA margin % | 19.7 | 27.2 | 26.6 | 22.5 |
| Net margin % | 2.2 | 6.2 | 6.6 | 4.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.3% | 18.6% |
| Profit CAGR | -5.9% | -12.2% |
4 · The owners
Who holds it, and are they adding?
Down 15.97 pts over 8 quarters.
Up 2.98 pts over 8 quarters.
Up 13.93 pts over 8 quarters.
+58 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.64 | 60.64 | 54.45 | 54.45 | 54.45 | 44.92 | 44.67 | 44.67 | -15.97 |
| FII | 5.66 | 5.66 | 6.04 | 6.61 | 7.39 | 7.52 | 8.14 | 8.64 | +2.98 |
| DII | 15.37 | 15.72 | 22.82 | 22.1 | 21.71 | 24.07 | 23.38 | 29.3 | +13.93 |
| Public | 18.12 | 17.76 | 16.5 | 16.69 | 16.33 | 23.41 | 23.75 | 17.2 | -0.92 |
Mutual fund holdings · Oct 2026
230 schemes hold this stock
172 the month before.
- ICICI Prudential Healthcare Fund5.3% of NAV
- quant Healthcare Fund5.06% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND3.7% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund3.69% of NAV
- ICICI Prudential Contra Fund3.22% of NAV
- SBI Contra Fund3.17% of NAV
- Nippon India Focused Fund3.05% of NAV
- ADITYA BIRLA SUN LIFE FOCUSED FUND2.9% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for BIOCON LTD. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about BIOCON LTD.
What is the BIOCON LTD. share price?
BIOCON LTD. (BIOCON) last closed at ₹364.75, up 0.77% on the day. Its 52-week range is ₹323.50 to ₹440.70.
What is the market cap of BIOCON LTD.?
BIOCON LTD. has a market capitalisation of about ₹58,863 crore. Its price-to-earnings ratio is 120.5.
How are BIOCON LTD.'s latest results?
BIOCON LTD. reported revenue of ₹4,389 crore for Sep 2026, up 2.2% from a year earlier. Net profit was ₹41 crore (down 51.2% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 44.67% in Sep 2026, down 15.97 points over 8 quarters.
Who owns BIOCON LTD.?
As of Sep 2026, shareholding was: Promoter 44.67%, FII 8.64%, DII 29.3%, Public 17.2%.
How many mutual funds hold BIOCON LTD.?
230 mutual fund schemes held BIOCON LTD. in October 2026. That compares with 172 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 03 Jul 2026 · Final Dividend - Rs. 0.5
- 04 Jul 2025 · Final Dividend - Rs. 0.5
- 05 Jul 2024 · Final Dividend - Rs. 0.5
- 07 Jul 2023 · Final Dividend - Rs. 1.5
- 30 Jun 2022 · Final Dividend - Rs. 0.5
- 18 Jul 2019 · Final Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.